Skip to content
‹ Back to IndustriesSciences

How Basic Chemicals are Being Impacted in the Supply Chain

Key Points: Supply Chain Issues are causing disruptions to the chemical industry. Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions. The big players figured out how to deal with disruptions in the supply chain. Commentary: Disruptions in the supply chain are causing problems across every industry. Basic chemicals, such as…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Basic ChemicalsChemical Supply ChainPrice SurgePvc
Share

Key takeaways

01

Key Points: Supply Chain Issues are causing disruptions to the chemical industry.

02

Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions.

03

The big players figured out how to deal with disruptions in the supply chain.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Key Points:

  • Supply Chain Issues are causing disruptions to the chemical industry.
  • Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions.
  • The big players figured out how to deal with disruptions in the supply chain.

Commentary:

Disruptions in the supply chain are causing problems across every industry. Basic chemicals, such as ethylene, PVC, and epoxy resins, are seeing price surges due to these disruptions. We asked Jimmy Jett, CEO of Integrity BioChem, about these demand increases and what sort of role does it play in the overall chemical supply chain issue.

Abridged Thoughts:

Obviously, demand. There is a lot of pent-up demand from the pandemic, as people start to consume more and get back on the roads and travel. You’re seeing a lot of demand. It is unfortunate that demand is spiking, as supply is dwindling. What you’re seeing is that the big players have more sophisticated supply chain systems and have gotten out ahead of it. Some great examples are you’ve seen some of the bigger companies that have even contracted their own fleet to move goods and services around the world. You’re seeing some of the larger players with a really solid plan to mitigate some of the supply chain issues, but the Tier Two and Three companies might not have the cash flow to go out and purchase six months worth of inventory. 

What Can the Pharma Industry Learn from Merck’s New Antiviral?

Will Consumers Be Seeing Higher Prices as the Result of the Tightened Supply Chain?

Video TranscriptExpand ↓

Disruptions in the supply chain are causing problems across every industry. Basic chemicals such as ethylene, PVC and epoxy resins are seeing price surges due to these disruptions. With that in mind, we asked Jimmy, CEO of integrity biochim. About this increases in the man and what sort of role does it play in the overall chemical supply chain issue? You know, obviously demand there's a lot of pent up demand from the pandemic as people start to consume more and get back on the roads and travel. You're seeing a lot of demand, and it's unfortunate that demand is spiking as supply is dwindling. So what you're seeing is the big players that have a more sophisticated supply chain system have gotten out ahead of it. Some great examples or you've seen a lot of the bigger companies that have even contracted their own fleet to move goods and services around the world. And so you're seeing some of the larger players with a really solid plan to mitigate a lot of the supply chain issues. But the tier two and tier three companies that might not have the cash flow to go out and purchase six months worth of inventory are feeling it the most and you're going to see. And then the reality is in the US that tier two and tier three support system in manufacturing than in the chemical space that goods and services, it makes up a massive percentage of the market. So you're going to see a very compressed manufacturing base that are able to get the products. And so with that are going to come a lot of delays. You can just expect, you know, lead times to go from 2 to three weeks to six months and even pushed out further. So it's going to be interesting as the market tries to correct. We already know what these issues are doing to chemicals such as ethylene, PVC and epoxy resins. But what about the sustainable, bio based chemicals? Are they being impacted similarly or in a completely different way? So the sustainable supply chain, you know, the surfactants or the based surfactants and the chemical side have not been impacted. But what you're going to find is that a lot of the technology out there, you obviously don't have the production capacity that is built into their traditional synthetic market. So a lot of the fermentation capacity has come a long way and you're going to see them surge over the next six months because they're going to be able to produce what they can. However, what they can produce is just a fraction of what the industry needs. A lot of the vegetative sources like integrity biochem uses, they're going to be more readily available as well, but they're emerging technologies and they might not have the adoption that traditional synthetics have. So it's going to be interesting to see how quickly you can get these chemistries into the supply chain and through the regulatory side in an expedited way to make an impact. Finding solutions to these supply chain issues is something every industry is trying to figure out when it comes to chemical producers. What strategies should they implement westjet? Should they be investing in New supply chain partnerships, new chemical compounds or new production workflows? And this is what he had to say. I think it's definitely a mix. I mean, you have to be looking at alternative supply partners immediately to secure the pent up demand that is required to run your business. But, you know, in a congruent path, you need to be also looking at New technologies that might supplement or even replace some of these existing technologies. You know, one of the things I love about this industry is that innovation is born in difficult supply markets. When there's challenges out there, a lot of new stuff is developed and a lot of new markets are created. So I'm excited to see what happens. I mean, America is we are excellent at adapting. And so I think we're going to see a lot of neat new technologies emerge and a lot of sustainable products that might have been on the sidelines are going to have a shot to come in and replace some of the sympathetics that you just can't get right now. Chemical energy and its demands is something that needs to be closely evaluated, especially when it's in high demand and a supply chain process is facing as many issues as it is. For more stories of energy and its supply chain effects, be sure to head to Marcus gmail.com as well as subscribe.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

AI shows up in all five tracks at ISPE's 2026 Annual Meeting

AI shows up in all five tracks at ISPE's 2026 Annual Meeting

ISPE's 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC explaining why AI appears across every track rather than in a standalone one. Deloitte's December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE's 2026 Annual Meeting has no dedicated AI track; program chairs expect AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte's December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own financial outlook but only 41% optimistic about the global economy, the mood the program is built for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation with tagged models enables tracking of tumor growth in the organ where it naturally occurs, supporting clinically relevant assessment of therapies delivered in that setting.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Clinical data harmonization is the bottleneck for life sciences AI

Clinical data harmonization is the bottleneck for life sciences AI

Life sciences companies moving AI from experimentation to scale keep running into messy trial data. One study can draw on EDC, health records, eCOA tools, wearables and imaging, and data teams at pharma SMEs often spend up to 80% of their time wrangling it. Commentators point to lakehouse architectures and data-cleansing AI agents, though the agents are still at proof of concept.

  • 01Treat automation gains as proof-of-concept for now; evaluate AI/harmonization choices based on data readiness, governance, and whether the architecture supports traceability and regulatory needs.

Sep 26, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512